Navigation Links
Armed antibody triggers remissions for Hodgkin's lymphoma
Date:11/3/2010

ere primarily at lower grades, including fever, diarrhea, nausea, low white blood cell counts and peripheral neuropathy nerve pain and/or numbness.

Anti-tumor effects included:

  • 17 objective responses (38 percent), 11 of which (25 percent) were complete remissions, defined as disappearance of all evidence of the disease. A partial response consists of a 50 percent decline in the cumulative diameters of known malignant lesions and no new lesions.
  • Half of patients (6 of 12) who received the maximum tolerated dose had an objective response.
  • CT scans showed that 36 of 42 (86 percent) evaluable patients had their tumors shrink.
  • 19 patients (43 percent) had stable disease.
  • Of 16 patients who had disease symptoms at baseline, 13 (81 percent) had their symptoms resolved during treatment regardless of their response status.

An independent, retrospective assessment of CT and positron-emission tomography scans showed similar responses 18 of 45 objective responses (40 percent) overall and 8 of 12 objective responses (67 percent) among those who received the maximum tolerated dose.

Median duration of objective response was 9.7 months, with median progression-free survival of 5.9 months.

About 80 percent of all Hodgkin lymphoma patients achieve long-term remission with standard chemotherapy regimens which may also include radiation therapy, Younes said. For those who are not cured with front line therapy, especially those whose disease relapses after autologous stem cell transplantation, the prognosis remains poor. About 1,300 people in the United States die from the disease annually.

An earlier clinical trial had shown that the CD30 antibody alone produced no objective responses among 38 Hodgkin lymphoma patients. Seattle Genetics developed the investigational drug brentuximab vendotin by linking monomethyl auristatin (MMAE) to the antibody to form a conjugate. MMAE inhibits tubul
'/>"/>

Contact: Scott Merville
smerville@mdanderson.org
713-792-0661
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Page: 1 2 3

Related biology technology :

1. Micromet to Provide Update on BiTE Antibody Development Programs at Upcoming Medical Conferences
2. OriGene Technologies, Inc. to Build the Worlds Largest TrueMAB(TM) Monoclonal Antibody Facility in Wuxi, China
3. Boehringer Ingelheim and Micromet Announce Global Collaboration for Multiple Myeloma BiTE Antibody
4. Precision Antibody Wins Contract to Develop Gold Standard Antibodies as Part of National Cancer Institutes Clinical Proteomics Technologies for Cancer (CPTC) Initiative
5. BioWa and NKTT Announce Licensing of BioWas POTELLIGENT(R) Technology For Use in Antibody Research and Development
6. Quest PharmaTech Acquires Late-Stage Immunotherapeutic Antibody Pipeline
7. Micromet Reports Interim Data from Phase 1 Study of BiTE Antibody MT110 for the Treatment of Solid Tumors
8. Avaxia Biologics Awarded Phase I SBIR Grant to Develop Antibody Therapeutic for Oral Mucositis
9. arGEN-X Raises EUR9.5 Million to put SIMPLE Antibody(TM) Platform to Work
10. First human gets new antibody aimed at hepatitis C virus
11. Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals Lead Antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/13/2014)... The “Global Synthetic Biology Market (2013-2018)”, analyses ... and challenges. , The global synthetic biology market ... Fisher Scientific, Inc. (U.S.), DuPont (U.S.), and Royal ... approximately ~65% of the total synthetic biology market. ... Report @ http://www.marketsandmarkets.com/Market-Reports/synthetic-biology-market-889.html , Thermo Fisher ...
(Date:12/13/2014)...  Vermillion, Inc. (NasdaqCM: VRML), a bio-analytical solutions company focused ... Veronica G. H. Jordan , Ph.D., and David ... bringing the total number of directors to eight, seven ... LaFrance , Chairman, President, and Chief Executive Officer of ... appointments of Veronica and David to our board of ...
(Date:12/13/2014)... SAN ANTONIO , Dec. 12, 2014 /PRNewswire/ ... presentation of data at the San Antonio Breast Cancer ... epoetin alfa plus best supportive care (BSC) versus BSC ... breast cancer receiving standard chemotherapy. This non-inferiority trial did ... out a 15 percent or greater increase in the ...
(Date:12/12/2014)... Pittcon is pleased to announce ... over 2,000 technical presentations offered in symposia, oral ... program covers a wide range of applications such ... discovery, environmental, food science, fuels/energy, genomics, lab management, ... The Technical Program begins on Sunday, March 8 ...
Breaking Biology Technology:Synthetic Biology Market to HIt $5.6304 Billion by 2018 - New Research Report by MarketsandMakets 2Synthetic Biology Market to HIt $5.6304 Billion by 2018 - New Research Report by MarketsandMakets 3Vermillion Strengthens Board of Directors with Appointments of Veronica Jordan, Ph.D., and David Schreiber 2Vermillion Strengthens Board of Directors with Appointments of Veronica Jordan, Ph.D., and David Schreiber 3Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 2Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 3Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 4Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 5Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 6Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 7Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 8Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 9Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 10Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 11Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 12Pittcon Announces a Diverse 2015 Technical Program - Renowned Speakers, Special Symposia and Co-programming 2Pittcon Announces a Diverse 2015 Technical Program - Renowned Speakers, Special Symposia and Co-programming 3
... 2 More than a dozen internationally renowned speakers, ... team, will be coming to New Haven, CT to ... symposium taking place March 23-24, 2009.The roster includes scientists ... creation of two new human embryonic stem cell lines ...
... Cephalon, Inc .,(Nasdaq: CEPH ) today ... worldwide rights to Lupuzor(TM), an investigational medication for the,treatment ... of the ImmuPharma Phase IIb study. Cephalon will assume ... commercialization of,the product. , ImmuPharma ...
... BioMed Realty Trust, Inc. (NYSE: BMR ) ... and year ended December 31, 2008 after the market closes ... Chief Executive Officer, and Kent Griffin, President and Chief Financial ... Pacific Time on Thursday, February 12, 2009 to discuss the ...
Cached Biology Technology:Obama Advisor Joins Connecticut and International Scientists at New Haven Stem Cell Symposium 2Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor 2Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor 3Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor 4Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor 5BioMed Realty Trust to Report 2008 Fourth Quarter and Year-End Results 2
(Date:12/5/2014)... Calif. , Dec. 4, 2014 ... has boosted investments in new testing and inspection ... also given rise to a range of innovative ... the requirements of Generation Y, which is generally ... As a result, product development strategies of test ...
(Date:11/21/2014)... According to a new market research report ... Control, Intrusion Detection, Parking Management, Under Vehicle Inspection), End ... - Global Forecasts to 2020", published by MarketsandMarkets, The ... $25 Billion in 2014 and is expected to reach ... 8.69%. Browse 116 market data Tables and ...
(Date:11/18/2014)... 18, 2014  The Secure Identity & Biometrics ... jointly announce the formation of The Airport Entry ... Identity and Biometric Entry and Exit Solutions ... official support from BORDERPOL, the international non-profit organization ... provide expertise regarding border security, traveler and migration ...
Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3
... Institute near Cambridge, supported by the Alzheimer,s Research ... Council (BBSRC), have discovered that the brain,s circuitry ... ageing such as Alzheimer,s disease. The findings were ... Alzheimer,s disease causes nerve cells in the ...
... The Stowers Institute,s Linheng Li Lab has identified the precise ... were published today in the Advance Online Publication of ... of the Institute,s support facilities to develop a new technology ... to monitor the dynamic behavior of stem cells. This technology ...
... NY, December 4, 2008Researchers are taking a closer look ... to demonstrate that inhibiting this biological route suppresses tumor ... ( GEN ). The pathway is involved in angiogenesis, ... part of the PI3/AKT/mTOR pathway, which plays a key ...
Cached Biology News:Maintaining the brain's wiring in aging and disease 2Stowers Institute's Linheng Li Lab expands understanding of bone marrow stem cell niche 2
Human Legumain Affinity Purified Polyclonal Ab...
Human Cystatin F MAb (Clone 292103)...
... Ac-DEVD-CHO is an inhibitor ... The concentration of inhibitor ... activity must be determined ... Ten micromolar inhibitor is ...
Human RELT/TNFRSF19L Affinity Purified Polyclonal Ab...
Biology Products: